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Edited by Lev KisselevAbstract The use of small molecule inhibitors in the study of
cellular processes is a powerful approach to understanding gene
function. During the course of a high throughput screen for novel
inhibitors of eukaryotic translation, we identiﬁed a number of
nucleic acid binding ligands that showed activity in our assay.
When tested on a panel of mRNA transcripts displaying diﬀerent
modes of translation initiation, these ligands showed a range of
biological activities – with some inhibiting both cap-dependent
and internal initiation and others preferentially blocking internal
initiation. We used this information to identify a novel threading
intercalator that inhibits Hepatitis C virus internal initiation.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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entry site1. Introduction
The modes by which the majority of small molecules bind to
nucleic acids are intercalation, groove binding, or a combina-
tion of the two. It is through these interactions that some nu-
cleic acid ligands exert their eﬀects on the cell, by modulating
or inhibiting essential nucleic acid-speciﬁc processes. Although
most nucleic acid ligands are used simply as probes in the
investigation of biochemical structure and dynamics, there
are several classes of intercalators, such as the anthracyclines
and actinomycins, that are common clinical antineoplastic
agents. By intercalating between base-pairs of DNA, they dis-
rupt both the activity of DNA and RNA polymerases, as well
as promote double-strand DNA breaks. It has been suggested
that the latter eﬀect is mediated through stabilization of a
topoisomerase II–DNA covalent complex, resulting in the
chemical lesion [1,2]. Although fragmentation of DNA and
inhibition of nucleic acid-speciﬁc enzymes are likely cytotoxic,
the basis for their anti-cancer/anti-growth eﬀects is not abso-
lutely clear. Indeed, anthracyclines also inhibit glycoprotein
biosynthesis [3], produce free radicals [4], and perturb mem-
brane structure and function [5]. In support of this, immobili-
zation of anthracyclines to solid support beads exerts a*Corresponding author. Fax: +1 514 398 7384.
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doi:10.1016/j.febslet.2004.06.103cytotoxic eﬀect that is distinct from eﬀects on DNA metabo-
lism [6].
There are several reports of nucleic acid binding ligands
interfering with the process of protein synthesis. Actinomycin
D inhibits protein synthesis in vivo by causing a decrease in
polysome loading [7,8] due to reduced binding of ribosomes
to mRNA templates during initiation [9,10]. These eﬀects are
not observed if actinomycin D is added to cell extracts, but
have been studied in lysates prepared from cells exposed to
actinomycin D [9], suggesting that the results are indirect
and require an intact cell. Dercitin [11] and chartreusin [12] ex-
ert inhibitory eﬀects in vivo on protein synthesis, although the
mechanism of action remains to be deﬁned. Ethidium bromide
[13] and acriﬂavine [14] have been reported to inhibit aminoa-
cylation of tRNAs in vitro. The intercalators NBQ (3-nitro-
benzothiazolo(3,2-a)quinolinium) and fagaronine have been
shown to inhibit protein synthesis in cell-free extracts, possibly
by aﬀecting elongation [15]. Although never formally shown, it
is expected that the eﬀects of nucleic acid binding ligands on
protein synthesis are a consequence of their RNA binding
properties.
Quite apart from their broad pharmacological applications,
the unique DNA/small-molecule interaction aﬀorded by nu-
cleic acid ligands has prompted much research into the design
of sequence-speciﬁc DNA compounds in an eﬀort to speciﬁ-
cally control gene expression [16]. Remarkable progress has
been achieved in the ability to target speciﬁc DNA sequences
with minor groove binding agents [17], to the point of generat-
ing functional transcriptional activators from synthetic hybrid
small-molecule/peptides [18]. However, targeting RNA has not
progressed as rapidly likely because the structure of RNA in
solution is considerably more complex and less predictable
than that of DNA. A single stretch of primary RNA sequence
often can fold into many distinct, but kinetically-equivalent,
three-dimensional structures. Additionally, the dynamic nature
of RNA structures, as well as the presence of associated pro-
teins that can displace all but the most strongly bound ligands
makes RNA an especially diﬃcult species to target using small-
molecules.
Nonetheless, recent experiments have shown the feasibility
of targeting speciﬁc mRNAs with small molecule ligands in or-
der to modulate gene expression by utilizing ligands that rec-
ognize speciﬁc RNA folds [19–21]. Other approaches in
targeting RNA employ threading intercalators [22,23] where
the intercalating group directs substituents into both grooves
of a duplex simultaneously for increased recognition [24]. We
have recently shown the feasibility of recruiting proteinblished by Elsevier B.V. All rights reserved.
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signed to realize a trimolecular complex between a RNA, pro-
tein, and small molecule [21]. These chemical inducers of
dimerization (CIDs) contain speciﬁc protein- and RNA-bind-
ing moieties that together serve to (i) induce proximity between
the targeted RNA and protein and, (ii) generate a trimeric
complex whose stability is greater than would be expected
based on the stabilities of the individual bimolecular compo-
nents. As a ﬁrst step towards developing CIDs, we sought to
ﬁrst identify small-molecule ligand(s) with RNA targeting
speciﬁcity. We designed a high throughput assay to identify
small-molecule inhibitors of cap-dependent and/or Hepatitis
C virus (HCV)-mediated translation. A number of nucleic acid
binding ligands showed activity in this assay and we character-
ized the mode of action of several of these. Using this informa-
tion, we then screened for and identiﬁed a threading
intercalator that preferentially targeted the HCV internal
ribosome entry site (IRES) and impaired its function in
translation.2. Materials and methods
2.1. General materials and methods
Restriction endonucleases, calf intestinal alkaline phosphatase, the
klenow fragment of DNA polymerase I, T4 DNA ligase, and SP6
RNA polymerase were purchased from New England Biolabs (Beverly,
MA). 5-3[H] cytidine triphosphate (20.5 Ci/mmol), [35S] methionine
(>1000 Ci/mmol) were obtained from Perkin Elmer Life Sciences (Bos-
ton, MA). Preparation of plasmid DNA, restriction enzyme digestion,
agarose gel electrophoresis of DNA and RNA, DNA ligation, and
bacterial transformations were carried out using standard methods
[25].
2.2. Discrete compound library screening
The discrete compound collection screened for activity consisted of
1680 synthetic and natural products from MicroSource Discovery
(Gaylardsville, CT) and 1905 compounds from the NCI-DTP Diver-
sity Set. Single compounds were obtained from Molecular Probes (Eu-
gene, OR) or from the Drug Synthesis and Chemistry Branch of the
National Cancer Institute and were generally dissolved in dimethyl
sulfoxide (DMSO). Equivalent amounts of solvent were included in
all in vivo and in vitro control reactions.
2.3. In vitro translations
Initial in vitro translation assays were performed with the bicistronic
mRNA reporter, (CAG)33/FF/HCV/Ren, in which the ﬁrst cistron en-
codes the ﬁreﬂy (FF) luciferase (luc) protein and in which the second
cistron encodes the renilla (ren) luciferase protein (Fig. 1A). In vitro
transcriptions were performed as previously described [20] using Bam-
HI linearized templates. Translations were performed in Krebs ascites
extracts as previously reported [20]. Translations in wheat germ and
Escherichia coli S30 extracts were performed as recommended by the
manufacturer (Promega Corp) (speciﬁc modiﬁcations are described
where applicable). FF and Ren luciferase activity was measured on a
Berthold Lumat LB 9507 luminometer as previously reported [26]. De-
tails on the construction of the bicistronic reporters pKS/FF/Ren,
pKS/FF/HCV/Ren and pKS/FF/EMC/Ren have been reported [27].
Plasmids pcDNA3/Ren/P2/FF [28] and pGEM3/Ren/CrPV/FF [29]
were kind gifts from Drs. Nahum Sonenberg (McGill University)
and Peter Sarnow (Stanford University), respectively.
2.4. Met-puromycin assays
Met-puromycin assays were performed as previously described [30].
Brieﬂy, reactions included 60 nM ribosomes, 2 nM 35[S] methionyl
tRNA, 400 lM puromycin, and 1 lM model mRNA, in a buﬀer con-
taining 500 lMGTP and 1.75 mMmagnesium acetate, and other com-
ponents as speciﬁed previously [30]. 80S complexes were performed
prior to addition of puromycin and inhibitor. Reactions proceededat 26 C for 12 min, with aliquots removed periodically and quenched
in 3 M sodium acetate, pH 5.1. Quenched samples were resolved by
cation-exchange TLC with a running buﬀer of 2 M NH4OAc in 10%
acetonitrile(pH5.2), and quantitated on a Fuji BAS2000 phosphoimager
by comparing the 35[S] Met-puromycin product to 35[S] Met
tRNA + 35[S] Met-puromycin. The observed rate constant at several
concentrations of inhibitor was measured and normalized to a reaction
performed in the absence of inhibitor.
2.5. Ribosome binding assays
Ribosome binding assays were performed as previously described
[20]. Essentially, 32[P] labelled mRNA was incubated in 25 ll of rabbit
reticulocyte lysate (Promega) at 30 C for 10 min in the presence of 0.6
mM cycloheximide or 1 mMGMP-PNP and 50 lM of candidate small
molecule ligand. The ﬁnal potassium acetate (KOAc) concentration
was adjusted to 150 mM. Initiation complexes formed were analyzed
by sedimentation through 10–30% glycerol gradients. Centrifugation
was for 3.5 h at 39000 rpm at 4 C in an SW40 rotor. Fractions of
500 ll were collected and radioactivity was determined by Cherenkov
counting in a liquid scintillation counter. The plasmids pSP6/CAT and
pSP6/TAR/CAT used to generate mRNA for binding experiments
have been previously described [31].
For electrophoretic mobility shift assays (EMSA), 40S ribosomal
subunits were isolated from rabbit reticulocyte lysate (Green Hectares)
essentially as described [32,33]. To generate IRES RNA complexes
with 40S ribosomes, radiolabelled RNA (HCV IRES; 0.6 · 106 cpm/
ug) was incubated with 4.5 pmoles of ribosomes in binding buﬀer
(20 mM Tris–HCl [pH 7.5], 2 mM DTT, 100 mM KOAc, 2.5 mM
MgCl2, and 0.25 mM spermidine) at 37 C for 10 min., then analyzed
on a 4% polyacrylamide gel (37.5:1, acrylamide:bisacrylamide [30].3. Results
We have developed a high throughput, multiplexed screen to
search for novel inhibitors of protein synthesis [27]. The assay
utilizes a bicistronic reporter mRNA construct to detect: (i)
small-molecule ligands that inhibit cap-dependent initiation
or that bind to the (CAG) repeats in the 5 0UTR to decrease
production of ﬁreﬂy luciferase protein, (ii) small molecule/
HCV IRES interactions that inhibit internal initiation, and
(iii) general inhibitors of protein synthesis aﬀecting the produc-
tion of both ﬁreﬂy and renilla proteins (Fig. 1A). During the
course of a pilot screen with this assay, we noticed that a signif-
icant number of inhibitory compounds identiﬁed were nucleic
acid binding agents. Moreover, a bioinformatics approach
(COMPARE analysis) performed by us to identify compounds
tested in the NCI Human Tumor Cell Line Anti-Cancer Drug
Screen (>41000 synthetic and natural product compounds)
for similarity of behaviour to 31 known protein synthesis inhib-
itors, also identiﬁed a number of nucleic acid binding com-
pounds as potential protein synthesis inhibitors [34].3.1. Diﬀerential eﬀect of nucleic acid binding ligands on protein
synthesis
Given the paucity of data regarding the eﬀects of intercala-
tors and groove binders on protein synthesis, we decided to
better characterize their role as inhibitors of this process, as
well as assess if there was any speciﬁcity to the mechanism
of inhibition by some of these compounds. We tested a number
of these compounds in Krebs translation extracts and found
that a large majority of these, but not all, were capable of
inhibiting protein synthesis when present at a ﬁnal concentra-
tion of 50 lM (Table 1). We performed a series of titrations in
translation extracts derived from Krebs cells with coralyne,
acriﬂavine (proﬂavine), ethidium bromide, a quinolinium
Fig. 1. Eﬀect of intercalators on translation in Krebs extracts. (A) Schematic diagram of pSP/(CAG)33/FF/HCV/Ren. To generate mRNA for in
vitro transcriptions, the plasmid was linearized with BamHI. The ﬁreﬂy luciferase coding region is denoted by an open box, whereas the renilla coding
region is denoted by a grey box. The SP6 promoter is denoted by a blackened box. The HCV IRES (indicated by a thickened line) allows for internal
initiation upstream of the renilla ATG. (B) Chemical structures of some of the intercalators used in this study. (C) Titration of various intercalators
in Krebs extracts. Translations were performed in the presence of the indicated amounts of compound and at a ﬁnal mRNA and K+ concentration of
5 lg/ml and 100 mM, respectively. Since the ﬁnal concentration of DMSO in the compound additions was 0.5%, control translation reactions
contained 0.5% DMSO. The obtained luciferase activities are normalized to the activity obtained in the control translations (which were set at one).
The relative ﬁreﬂy luciferase values are represented by white bars and the relative renilla values are represented by grey bars. Translations were
performed 3–4 times and the average values are presented along with the standard error of the mean. (D) Relative translation eﬃciencies of ﬁreﬂy and
renilla production from (CAG)33/FF/HCV/Ren mRNA in the presence of diﬀerent intercalators. This experiment represents one of those used in C
above. Following in vitro translations in the presence of the indicated amounts of intercalator and 35[S] methionine, samples were treated in SDS
sample buﬀer and electrophoresed into a 10% SDS/polyacrylamide gel. The gel was treated with EN3Hance, dried, and exposed to X-Omat (Kodak)
ﬁlm. The concentration and nature of the intercalator in the translation mix is indicated above the panel. The arrow and arrowhead indicate the
position of migration of ﬁreﬂy and renilla luciferase, respectively. The positions of molecular mass markers (NEB) are indicated to the left. (E)
Translation reactions in extracts prepared from HeLa programmed with (CAG)33/FF/HCV/Ren. mRNA were performed as indicated by the
manufacturers recommendation (Promega Corp.) at an mRNA concentration of 5 lg/ml and a ﬁnal K+ concentration of 150 mM. The obtained
luciferase activities are normalized to the activity obtained in the control translations (which were set at one). The relative ﬁreﬂy luciferase values are
represented by white bars and the relative renilla values are represented by blackened bars.
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Table 1
Inhibition of protein synthesis by nucleic acid intercalators
Name NSC#a % Inhibition ﬁreﬂy luciferaseb,c % Inhibition renilla luciferasea,b
Ethidium bromide >95% >95%
Dihydroethidium No inhibition 38 ± 8%
DAPI >95% >95%
Methylene blue >95% >95%
7-Aminoactinomycin 44 ± 3% 49 ± 2%
Hydroxystilamidine methene sulfate >95% >95%
Propidium iodide >95% >95%
Acriﬂavine >95% >95%
Actinomycin D No inhibition No inhibition
Quinolinium derivative 86372 >95% >95%
Naphthacenone derivative 254681 81 ± 1% 90 ± 1%
Nogalamycin 82892 >95% >95%
Ellipticine derivative 176327 >95% >95%
Ellipticine derivative 311152 >95% >95%
Ellipticine derivative 311153 >95% >95%
Ellipticine derivative 359449 >95% >95%
Coralyne No inhibition No inhibition
Mitoxantrone >95% >95%
Hoechst 33258 >95% >95%
a Refers to the NCI-DTP unique identiﬁer number.
b Tested at 50 lM ﬁnal concentration. Represents the percent inhibition obtained in the presence of compound compared to parallel translations
performed in the absence of compound.
c Average of two independent experiments. Translations were performed in Krebs extracts programmed with 5 lg/ml (CAG)33FF/HCV/Ren mRNA.
82 A. Malina et al. / FEBS Letters 579 (2005) 79–89derivative (NSC 86372), doxorubicin, actinomycin D, and
Hoechst 33258 (Fig. 1B). Krebs extracts were used since these
faithfully recapitulate cap-dependent translation [35]. This
experiment allowed us to determine the relative activity of each
compound and assess the eﬀects on cap- or IRES-dependent
translation (Fig. 1C and D). The results suggest three diﬀerent
modes of action by these compounds on eukaryotic protein
synthesis (Fig. 1C and D). (I) Coralyne and actinomycin D dis-
played little inhibition of translation from either ﬁreﬂy or renil-
la cistrons at 50 lM. (II) Doxorubicin, a quinolinium
derivative (NSC 86372), and Hoechst 33258 inhibited expres-
sion of both cistrons in a dose-dependent fashion (Fig. 1C
and D). (III) Acriﬂavine and ethidium bromide exerted a
dose-dependent inhibition of protein synthesis but did not
equally aﬀect translation from both cistrons (Fig. 1C and D).
At high concentrations (50 lM), translation of both ﬁreﬂy
and renilla ORFs (open-reading frames) are inhibited, whereas
at 10 lM expression from the renilla coding region is aﬀected
more than that from the ﬁreﬂy cistron (Fig. 1C and D). When
acriﬂavine and ethidium bromide were tested in a diﬀerent
translation system – one prepared from HeLa cells [which also
supports cap-dependent translation] (Fig. 1E), similar results
as in Krebs extracts were obtained. That is, inhibition of ﬁreﬂy
and renilla luciferase was observed at 50 lM, whereas at 10
lM, expression from the renilla ORF was aﬀected to a greater
extent than that from the ﬁreﬂy cistron (Fig. 1E).
To assess if the observed inhibition on translation by the nu-
cleic acid binding ligands were speciﬁc to translation extracts
prepared from mammalian cells, we tested their inhibitory po-
tential in a plant translation system derived from wheat germ
(Fig. 2). Since the HCV IRES is not active in wheat germ ex-
tracts (J.P., unpublished data), we measured only ﬁreﬂy lucif-
erase production (Fig. 2A). Consistent with results obtained in
Krebs extracts, actinomycin D had little eﬀect on protein syn-
thesis in wheat germ extracts up to a ﬁnal concentration of 50
lM (Fig. 2A). However, the quinolinium derivative (NSC86372), Hoechst 33258, acriﬂavine, and ethidium bromide each
showed dose-dependent inhibition of translation indicating
that the eﬀect on protein synthesis by these compounds is
not extract dependent (Fig. 2A). One could argue that the ob-
served eﬀect on translation by the RNA binding ligands was
due to mRNA degradation, stimulated by the presence of
intercalators in the extracts. To directly address this issue,
we examined the stability of (CAG)33/FF/HCV/Ren mRNA
under translation conditions in wheat germ extracts in the ab-
sence or presence of ethidium bromide or acriﬂavine (Fig. 2B).
Re-isolation of radiolabeled (CAG)33/FF/HCV/Ren mRNA
transcripts from programmed wheat germ translation extracts,
followed by separation on formaldehyde agarose gels, indi-
cated no eﬀect on mRNA stability by either ethidium bromide
or acriﬂavine (Fig. 2B). Thus, the observed eﬀects of these
intercalators on translation is unlikely to be due to a nucleo-
lytic activity associated with their presence in the extracts.
3.2. Nucleic acid binding ligands inhibit peptidyl transferase
The nucleic acid binding ligands could be acting at diﬀerent
or multiple steps in the translation process, including intiation,
elongation, or termination. To begin unraveling this, we as-
sessed the eﬀects of these compounds on translation initiation
by performing ribosome binding studies (Fig. 3A). In this as-
say, 80S initiation complexes are formed on radiolabelled
capped CAT mRNA templates in the presence of a known
inhibitor of elongation (cycloheximide [CHX]) and a RNA
binding ligand. The 80S initiation complex is separated from
unbound mRNA by centrifugation through a sucrose gradient
and collected fractions are assayed for 80S ribosomes bound to
32[P] labeled mRNA. Should the nucleic acid ligand inhibit ini-
tiation, a reduction in the amount of 80S ribosome–mRNA
complex, relative to cycloheximide alone, is expected. Transla-
tion initiation of the particular mRNA (CAT) used in this as-
say is cap-dependent (data not shown) and we are therefore
only assessing eﬀects on cap-dependent initiation. At 50 lM,
Fig. 2. Eﬀects of intercalators on translation in wheat germ extracts. (A) Translation reactions in wheat germ extracts programmed with (CAG)33/
FF/HCV/Ren. mRNA were performed as indicated by the manufacturers recommendation (Promega Corp.) at an mRNA concentration of 5 lg/ml
and a ﬁnal K+ concentration of 150 mM. Since the HCV IRES is inactive in wheat germ extracts, only ﬁreﬂy luciferase activity was assessed and is
plotted relative to the values obtained from control translations containing 0.5% DMSO (which were set at 1). The concentration and nature of the
intercalator present in the translation reaction is indicated below the panel. Each data point represents the average of at least two translations and the
standard error is shown. The relative ﬁreﬂy luciferase values are represented by white bars. (B) Relative stability of (CAG)33/FF/HCV/Ren mRNA in
wheat germ extracts in the presence of ethidium bromide or acriﬂavine. Wheat germ extracts were programmed with 32P labelled (CAG)33/FF/HCV/
Ren mRNA and incubated for the indicated amounts of time. Messenger RNA was then isolated from the translation reactions, fractionated on a
1.4% agarose/formaldehyde gel, and quantitated on a Fuji BAS2000 with a Fuji imaging screen. A representative autoradiograph from one
experiment is shown. The percent relative stability of each time point (and standard error of the mean) is indicated below each lane and is an average
from four experiments. Values were set relative to the value obtained at the beginning of the experiment (T = 0 min). The time points and the
presence or absence of 50 lM ethidium bromide or acriﬂavine in the translation reaction is indicated above the panel.
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rubicin, ethidium bromide, and acriﬂavine) prevented the for-
mation of 80S ribosome–mRNA complex in the presence of
cycloheximide (Fig. 3A and B), indicating that these com-
pounds inhibit an event downstream of the cap-dependent ini-
tiation process – perhaps, elongation and/or termination.
These results argue against the possibility of these compounds
signiﬁcantly inhibiting any of the translation initiation factors.
To gain insight into the possible mechanism of inhibition at
the level of elongation by these compounds, we tested whether
nucleic acid ligands could inhibit peptidyl transferase activity.
We focused our attention on ethidium bromide and acriﬂavine
in order to dissect the multiple eﬀects exhibited by these com-
pounds, since at lower concentrations (10 lM) they appeared
to exert diﬀerent eﬀects on ﬁreﬂy and renilla expression (Fig.
1C and D). To this end, we utilized the puromycin assay. Inthis assay, [35S] methionine-charged tRNA (Met-tRNAi) is
bound to the P-site of an 80S ribosomal complex. Because
puromycin (an analog of the 3 0-end of charged tRNAs) is
capable of binding to the A-site of the ribosome and reacting
with the ester linkage of Met-tRNAi to produce [35S] methio-
nine-puromycin (Met-Puro), eﬀects by small molecules on the
peptidyl transferase reaction can be monitored by assessing the
rates of radiolabeled dipeptide formation. Inhibition of Met-
Puro production was observed when either ethidium bromide
or acriﬂavine was included in the puromycin assay (Fig. 4A
and B). Varying the concentration of both compounds pro-
duced a dose–response curve (Fig. 4B), in which the IC50 of
both intercalators ranged from 15 to 25 lM. This is consis-
tent with the observed inhibition of expression of both ﬁreﬂy
and renilla cistrons at 50 lM (Fig. 1C and D). However, at
10 lM where peptidyl transferase activity is not signiﬁcantly
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Fig. 3. Initiation complex formation on capped CAT mRNA in the presence of intercalators. (A, B) Initiation complex assembly in the presence of
cycloheximide (CHX) and Hoechst 33258, doxorubicin, ethidium bromide, or acriﬂavine. 32P labelled CAT mRNA was used as mRNA template and
binding reactions were performed in the presence of 600 lM cycloheximide; 600 lM cycloheximide and 50 lM Hoechst 33258; or 600 lM
cycloheximide and 50 lM doxorubicin; (B) 600 lM cycloheximide and 50 lM ethidium bromide; or 600 lM cycloheximide and 50 lM acriﬂavine.
Fractions from each sucrose gradient were collected using a Brandel Tube Piercer connected to an ISCO fraction collection, and were individually
counted. Total counts recovered from each gradient and the percent mRNA bound to 80S complexes were: CAT mRNA/cycloheximide [73855 cpm,
22% binding]; CAT mRNA/cycloheximide + Hoechst 33258 [73125 cpm, 22% binding]; CAT mRNA/cycloheximide + doxorubicin [71954 cpm, 21%
binding]. (B) CAT mRNA/cycloheximide + ethidium bromide [46036 cpm, 20% binding]; CAT mRNA/cycloheximide + acriﬂavine [46307 cpm, 18%
binding].
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cistron.
3.3. Ethidium bromide and acriﬂavine inhibit initiation on the
HCV and CrPV IRESes
Inhibition of renilla luciferase translation by 10 lM ethi-
dium bromide and acriﬂavine from the (CAG)33/FF/HCV/
Ren template should be at the level of initiation (Figs. 1
and 4). At high concentrations, peptidyl transferase activity
is inhibited, and consequently translation of both cistrons.
However, at 10 lM, while the peptidyl transferase is mini-
mally aﬀected, we postulate that ethidium bromide and acri-
ﬂavine bind to the highly structured HCV IRES to inhibit
initiation. To explore this possibility, electrophoretic mobility
shift assays (EMSAs) were performed with puriﬁed rabbit
reticulocyte 40S ribosomal subunits and 32[P] labeled HCV
IRES RNA in the presence of ethidium bromide or acriﬂa-
vine (Fig. 4C). Both compounds inhibited HCV IRES-40S
ribosome binding in a dose-dependent fashion, demonstrating
90–95% inhibition at 50 lM and 65–75% inhibition at 10
lM. These results suggest a direct eﬀect on ribosome binding
to the HCV IRES mediated by ethidium bromide or acriﬂa-
vine. They also contrast those results obtained in the ribo-
some binding experiments utilizing the cap-dependent CAT
mRNA template (Fig. 3).
The HCV IRES is highly structured which may explain the
diﬀerent eﬀects of the nucleic acid binding ligands on internal
initiation. We therefore tested the eﬀect of acriﬂavine on trans-
lation of mRNAs harboring diﬀerent viral IRESes – derived
from EMCV (encephalomyocarditis virus), poliovirus, and
cricket paralysis viruses (CrPV) (Fig. 5A). At 50 lM, acriﬂa-
vine signiﬁcantly inhibited translation from both ﬁreﬂy and re-nilla cistrons for all constructs tested (Fig. 5B). At 10 lM, the
translation of both ﬁreﬂy and renilla ORFs were similarly af-
fected when expressed from the FF/Ren, FF/EMC/Ren, and
Ren/P2/FF mRNAs (Fig. 5B). However, translation of ﬁreﬂy
luciferase driven from the CrPV IRES was found to be prefer-
entially inhibited compared to that of renilla luciferase (3-
fold diﬀerence) (Fig. 5B). At 2 lM, only slight inhibitory
eﬀects on translation of both cistrons for all constructs was
noted. We observed similar results when ethidium bromide
was used in this assay (A.M. and J.P., data not shown).
3.4. Structure activity relationships analysis of acridine based
nucleic acid binding ligands
Acriﬂavine is a mixture of 3,6-diamino-10-methylacridinium
chloride and 3,6-acridinediamine. To assess the inhibitory po-
tential of the individual components as well as a number of
other structurally related compounds, additional titrations
were performed with (CAG)33/FF/HCV/Ren mRNA (Fig.
6A). 3,6-diamino-10-methylacridinium chloride and 3,6-acrid-
inediamine inhibited both ﬁreﬂy and renilla luciferase activity
at 50 lM (Fig. 6A). At 10 lM, both showed preferential inhi-
bition of renilla expression, similar to what was observed with
the acriﬂavin mixture (Fig. 6A). On the other hand, acridine
and amsacrine did not signiﬁcantly aﬀect synthesis of ﬁreﬂy
or renilla luciferase when present up to 50 lM in the transla-
tion reaction. Acridine orange, acridine yellow, and quinacrine
all reduced synthesis of both proteins at 50 lM, whereas at 10
lM, acridine orange and acridine yellow showed a moderate
reduction in renilla luciferase synthesis (2-fold) while that
of ﬁreﬂy luciferase was only marginally aﬀected (25%). Inter-
estingly, quinacrine showed no eﬀect on ﬁreﬂy or renilla pro-
duction at 10 lM ﬁnal concentration.
Fig. 4. Ethidium bromide and acriﬂavine inhibit peptidyl transferase. (A) Formation of 35[S] Met-Puro was followed using cation-exchange TLC. A
kinetic analysis in which a single concentration (50 lM) of ethidium bromide or acriﬂavine was used in the Met-Puro assay is shown. The positions of
migration of 35[S] Met-tRNAi, free
35[S] methionine, and the 35[S] Met-Puro product are indicated. (B) Dose–response curve showing the eﬀect of
ethidium bromide and acriﬂavine concentration on 35[S] Met-Puro production. Each points represents the average of three experiments, and the
standard deviation is shown. (C) Electrophoretic mobility shift assay with 40S ribosomes and 32[P] labelled HCV IRES. Ribosome/HCV IRES
complexes were formed in the presence or absence of acriﬂavine or ethidium bromide, resolved on 4% polyacrylamide gels, and dried. The control
reaction lacking 40S ribosomes gave no signal on the autoradiograph (data not shown). Gels were exposed to X-OMAT (Kodak) ﬁlm and the percent
inhibition of complex formation obtained is shown below the panel.
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described as novel RNA-binding ligands [36,37]. 9-Anilinoac-
ridine-4-carboxamides can act as threading intercalators,
wherein the core acridine moiety stacks between base-pairs
and directs its substituents into both grooves of the RNA du-
plex [22,23]. A small collection of these PACs were tested to
determine their eﬀects on HCV expression (Fig. 6B and data
not shown). One of these, PAC-6, inhibited HCV IRES medi-
ated renilla expression at 50 lM, but had no eﬀect on cap-
dependent ﬁreﬂy expression (Fig. 6B). The presence of 2 lysine
residues on the peptide moiety was important to the mode of
action of PAC-6, since replacement of one of the residues by
glycine (PAC-5), serine (PAC-11), or alanine (PAC-13) de-creased the ability of PAC-6 to preferentially inhibit HCV
IRES-driven expression (Fig. 6B). A control peptide (RGKK),
containing the sequence of the PAC-6 side-chain was unable to
recapitulate the diﬀerential eﬀect on translation (Fig. 6B). To
assess if PAC-6 was exerting an eﬀect on ribosome binding
of the HCV IRES, we performed EMSAs with puriﬁed 40S
ribosomes and 32[P] labeled HCV IRES (Fig. 6C). At 50 lM,
this compound inhibited ribosome binding on the HCV IRES
template 3-fold, whereas PAC-5 had little aﬀect on HCV
IRES/ribosome binding. These results, taken together with
the translation data in Fig. 6B, indicate that PAC-6 is likely
inhibiting translation of the renilla cistron by inhibiting ribo-
some binding to the HCV IRES.
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four experiments and the standard error of the mean is also shown.
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We have investigated the mode of action of a number of
RNA binding ligands on protein synthesis. At relatively high
concentrations (50 lM) many of the tested compounds were
active in an in vitro translation extract and inhibited expres-
sion of both cistrons from the bicistronic mRNA, (CAG)33/
FF/HCV/Ren (Fig. 1). For two compounds tested (ethidium
bromide and acriﬂavine) we noted that they inhibited pepti-
dyl transferase activity with an IC50 of 15–25 lM (Fig. 4B).
Hoechst 33258 completely inhibited peptidyl transferase
activity, whereas doxorubicin and the quinolinium com-
pound (NSC 86372) did not inhibit peptidyl transferase at
50 lM (SK, data not shown). At 10 lM, ethidium bromide
and acriﬂavine did not signiﬁcantly aﬀect cap-dependent
expression (ﬁreﬂy luciferase) from the (CAG)33/FF/HCV/
Ren transcript (Fig. 1), but did display a complex mode
of action since at concentrations below the IC50 for peptidyl
transferase inhibition, they blocked internal initiation from
the highly structured HCV IRES (Fig. 1). We demonstrated
that this was a consequence of inhibiting ribosome bindingto the HCV IRES template (Fig. 4C). This eﬀect was also
observed with the CrPV IRES (Fig. 5). In ribosome binding
assays, Hoechst 33258 did not prevent 40S ribosomes from
binding to the HCV IRES (A.M., data not shown) consis-
tent with more global eﬀects on translation observed with
this compound. Additionally, the threading intercalator
PAC-6 was capable of preferentially inhibiting internal initi-
ation, by preventing ribosome binding to the HCV IRES
(Fig. 6). It is unlikely that these compounds inhibit a general
translation initiation factor since no eﬀect on ribosome
recruitment on CAT mRNA was observed (Fig. 3).
Two of the intercalators tested, coralyne and actinomycin
D, had no discernible eﬀect on translation of the (CAG)33/
FF/HCV/Ren reporter in Krebs extracts (Fig. 1), wheat germ
extracts (Fig. 2), and rabbit reticulocyte lyates (data not
shown). Other compounds, such as CC1065 [38] and deriva-
tives of naphthalic acid [39], have been shown to inhibit syn-
thesis of both DNA and RNA, but exerted very little eﬀect
on protein synthesis. These results are consistent with a se-
quence or structural selectivity requirement for the activity
of nucleic acid-intercalative compounds on protein synthesis.
Fig. 6. Structure/activity relationships of acridine analogues on in vitro translation in Krebs extracts. Translations were performed as indicated in
Section 2. (A) Titration of acridine derivatives in Krebs extracts. The obtained luciferase activities were normalized to the activity obtained in the
control translations (which were set at one). The number of experiments performed with each compound and from which the averages are derived are
denoted in parentheses above the bar graphs. The chemical structures of the analogues are indicated above the panel. (B) Titration of acridine-
peptide threading intercalators in Krebs extracts. The number of experiments performed with each compound and from which the averages are
derived are denoted in parentheses above the bar graphs. The tetrapeptide RGKK was used as a negative control. The core structure of the threading
intercalators is shown to the right. (C) Electrophoretic mobility shift assay with 40S ribosomes and 32[P] labelled HCV IRES. Ribosome/HCV IRES
complexes were formed in the presence of the threading intercalators PAC-5 or PAC-6 resolved on 4% polyacrylamide gels and dried. Gels were
exposed to X-OMAT (Kodak) ﬁlm and the percent binding relative to the control reaction (containing 0.5% DMSO) is indicated below the panel.
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ular structures that favor RNA over DNA interactions
among intercalators [40,41], although threading intercalators
can bind to certain sites on RNA with higher aﬃnity than
to B-form DNA duplexes [37].
We have not characterized doxorubicin, the quinolinium
derivative (NSC 86372), or Hoechst 33258 to the same extent
as acriﬂavine and ethidium bromide, and our results do not
eliminate the possibility that these compounds also exert
structure-speciﬁc eﬀects given the appropriate RNA target.
The design of potent antagonists of speciﬁc RNAs is of great
interest and importance. Indeed, Hoechst 33258-binding
RNA aptamers have been engineered into the 5 0UTR of
mRNA reporters and shown to mediate inhibition of transla-
tion in direct response to this compound [19]. Nucleic acid-
binding ligands have been shown to interact speciﬁcally with
the 5 0UTR of thymidylate synthase, as well as to the TAR
RNA element of HIV-1 [42–44]. A protein/RNA interaction
between the U1A-RNA complex has been disrupted by an
aminoacridine derivative [45]. Thus, binding to appropriate
RNAs can lead to gene-speciﬁc eﬀects by nucleic acid binding
ligands.
Structure–activity relationships of the acridine derivatives
yielded interesting insight into the functional groups required
for inhibition of HCV-mediated initiation (Fig. 6). Unsubsti-
tuted acridine did not inhibit translation of either ﬁreﬂy or
renilla luciferase at any concentration tested. The addition
of two primary amino groups at the 3 and 6 positions gener-
ated compounds that were capable of preferentially inhibiting
renilla luciferase (Fig. 6, compare the activity proﬁle of 3,6-
acridinediamine, 3,6-diamino-10-methylacridinium chloride,
and acridine yellow). However, methylating these amino
groups (as in acridine yellow) appears to slightly impair the
ability to preferentially inhibit HCV-driven translation. The
threading intercalator, PAC-6, had signiﬁcantly improved
biological properties (compared to many of the acridine
derivatives), since global peptidyl transferase was no longer
aﬀected (as inferred by the ability to translate the product
of the ﬁrst cistron (Fig. 6B)), but the HCV IRES inhibitory
properties were still retained (Fig. 6B and C).
Taken together, the data suggest a model whereby some
intercalators (e.g., ethidium bromide and acriﬂavine) or
threading intercalators inhibit initiation by binding to highly
structured RNA templates. The ability of ethidium bromide
or acriﬂavine to inhibit HCV and CrPV mediated initiation
is consistent with this notion (Figs. 1 and 5). However, nei-
ther compound is capable of preferentially inhibiting EMC-
or poliovirus-mediated translation, although both of these
IRESes also adopt complex tertiary folds. The explanation
for this may reside in the fact that the canonical factor
requirement for ribosome binding to the EMC and poliovi-
rus IRESes diﬀer from those required for the HCV and
CrPV IRESes (for a review, see [46]). The HCV IRES can
directly recruit the 43S complex and by interacting directly
with the 40S ribosomal subunit and eIF3 [47]. Aside from
eIF2/GTP/Met-tRNAi and eIF3, no other initiation factor
appear necessary for 80S initiation complex formation on
the HCV IRES [32,46]. Initiation on the CrPV IRES re-
quires no initiation factors to recruit 80S ribsomes [47]. In
contrast, internal initiation on the picornaviral EMC and
poliovirus IRESes require IRES transacting factors (ITAFs),
as well as a larger complement of canonical initiation fac-tors, including eIF4F or eIF4A and the central third of
eIF4G to which eIF4A binds (reviewed in [46]). The require-
ment for helicase activity (eIF4A) for initiation on poliovirus
and EMCV template may decrease the eﬃciency by which
intercalators can inhibit initiation on these 5 0UTRs. On
the other hand, recognition of HCV or CrPV RNA struc-
tural features by ribosomes is required for recruiting 80S
ribosomes. Thus, disruption of structural features by com-
pounds like ethidium bromide, acriﬂavine, or PAC-6 may
be expected to disrupt ribosome binding. An alternative
explanation is that these compounds bind to ribosomes, ren-
dering them particularly sensitive to initiation on highly
structured mRNA templates, such as those found in the
HCV or CrPV 5 0UTRs. Our study does not eliminate the
possibility that these inhibitors exert additional eﬀects on
the translation apparatus, not detectable in, or probed by,
our current assays.
Ethidium bromide has been shown to selectively bind duplex
RNA adjacent to single nucleotide bulges [48]. Furthermore, it
has been recently demonstrated that threading intercalators
structurally similar to PAC-6 bind preferentially to duplex
RNA sites ﬂanked by non-Watson–Crick structural elements
[37]. Thus, the ability of ethidium bromide, acriﬂavine, and
PAC-6 to selectively block HCV IRES function may arise
from their ability to bind to site(s) in the IRES that supports
high aﬃnity interaction with an intercalating ligand having
the appropriate structure. This provides another possible
explanation for a lack of inhibition on EMC and poliovirus
IRES function since these RNAs may not have the ‘‘selective’’
binding site for the intercalating ligands. Identiﬁcation of this
putative binding site on the HCV IRES for these compounds
may provide a clearer picture for the basis of the observed
selectivity.
Of the peptide-acridine conjugates tested, PAC-6 was able
to discriminate between cap-dependent and internal initia-
tion on the (CAG)33/FF/HCV/Ren template (Fig. 6B). This
compound prevented initiation on the HCV IRES (Fig 6C)
and presumably achieves a degree of speciﬁcity, perhaps
by the appropriate placement of the charged lysine side-
chains into the major groove of the RNA duplex. To ex-
pand on the theme of threading intercalators in controlling
targeting speciﬁcity, one could also exploit the modularity
of synthesizing the PACs to generate chemical inducers of
dimerization [21]. Speciﬁcally, a bivalent molecule in which
one moiety is a RNA binding ligand, and the second moiety
is a protein binding ligand (e.g., a tissue speciﬁc protein or
in the speciﬁc case of HCV, a viral protein) could be used to
generate a protein/RNA complex suﬃciently stable to inhibit
mRNA translation [21]. In sum, our results have provided
insight into the mechanism by which some RNA binding li-
gands can inhibit global protein synthesis by aﬀecting ribo-
some function, as well as identifying a threading
intercalator that demonstrates some degree of speciﬁcity in
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